Call Us Toll Free: 1-800-388-9993

_______________________

Dear DRIP Investors,


We have been helping people enroll in DRIPs since 1986. Many of our subscribers have written to express their thanks and describe the outcome of their DRIP investments. It has been a source of pride and our great pleasure to have assisted in your efforts to secure financial security.


However, after 35 years we have decided to stop fulfilling orders for enrollments after the March cycle. Moneypaper, via the directinvesting.com website, will continue to provide information about DRIPs and the enrollment process.


As always, good luck,

Vita Nelson


 

 

 

 

Bristol-Myers Squibb Co. (BMY)

Available from the Temper Enrollment Service: No


Last Update On: 01/07/2021:

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor to treat human immunodeficiency virus (HIV) Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, Ubiquigent Limited, Checkmate Pharmaceuticals, and Sensyne Health plc clinical collaboration with NeoImmuneTech, Inc. partnership with Astrazeneca Plc a discovery collaboration with Insitro, Inc. and collaboration with Schrödinger, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. **Taken from Yahoo Finance**

Industry: Pharmaceutical & consumer products
Minimum Investment: $50.00
Maximum Investment: $10,000/month
Shares to qualify: 1
Recent Price: 66.32
Investing Fee: $5+6¢/sh.
Fee for Dividends: $0(<100sh); 5%(to $3)(>100sh.)

! = Company pays fees

Information is based on an annual survey and updated when company changes become available.

Click for Español

FOR MORE
INFORMATION

And a free copy of The Moneypaper's direct investing brochure, please enter your contact information below.

You will also be signed up to receive our monthly stock special.

You can unsubscribe at any time. We do not share your email with anyone.

By email, you get the Monthly “Stock Special,” where the service fee for enrollment in a great DRIP stock is reduced.

* Required Field.